SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    James B. Macdonald, Brooke Macdonald, Loren E. Golitz, Patricia LoRusso, Aleksandar Sekulic, Cutaneous adverse effects of targeted therapies, Journal of the American Academy of Dermatology, 2015, 72, 2, 221

    CrossRef

  2. 2
    Raji Shameem, Mario Lacouture, Shenhong Wu, Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials, Acta Oncologica, 2015, 54, 1, 124

    CrossRef

  3. 3
    Denise A. Yardley, Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists, Clinical Breast Cancer, 2014, 14, 5, 297

    CrossRef

  4. 4
    Janelle Nicole Ruiz, Viswanath Reddy Belum, Patricia Creel, Allen Cohn, Michael Ewer, Mario E. Lacouture, Current Practices in the Management of Adverse Events Associated With Targeted Therapies for Advanced Renal Cell Carcinoma: A National Survey of Oncologists, Clinical Genitourinary Cancer, 2014, 12, 5, 341

    CrossRef

  5. 5
    Lucie Peuvrel, Brigitte Dréno, Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management, American Journal of Clinical Dermatology, 2014, 15, 5, 425

    CrossRef

  6. 6
    Lokesh Kumar Jha, Sandeep Mukherjee, A worldwide yearly survey of new data in adverse drug reactions, 2014,

    CrossRef

  7. 7
    David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas, Joseph Posluszny, Stephen Saletan, William Berg, Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases, Annals of the New York Academy of Sciences, 2013, 1291, 1
  8. 8
    Mary E. Peterson, Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial, Supportive Care in Cancer, 2013, 21, 8, 2341

    CrossRef